Bristol-Myers Squibb reports further positive trial data for Opdivo

Bristol-Myers Squibb has announced new clinical trial data further demonstrating the benefits offered by its cancer therapy Opdivo.

Overall survival data from the phase II CheckMate -069 study showed the effectiveness of a combination of Opdivo and Yervoy in patients with previously untreated advanced melanoma. The combination demonstrated a higher two-year overall survival compared to Yervoy alone.

The safety profile of the combination regimen was also shown to be consistent with previously reported studies.

Meanwhile, results from CheckMate -141 – a phase III open-label randomised trial – showed the overall survival benefits associated with Opdivo among patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

It was shown that Bristol-Myers Squibb's therapy delivered a 30 percent reduction in the risk of death over the comparator therapies used in the trial.

Dr Jean Viallet, global clinical research lead for oncology at Bristol-Myers Squibb, said: "These findings are supportive of our immuno-oncology research goal to study potential treatment options for their ability to help patients with difficult-to-treat cancers achieve long-term survival."